Australian schizophrenia care and assessment programme: Real-world schizophrenia: Outcomes

Australian and New Zealand Journal of Psychiatry

Volumn 41, Issue 12, 2007, Pages 969-979

  Kulkarni, Jayashri ^a   de Castella, Anthony R ^a   Filia, Kate M ^a   Filia, Sacha ^a   Marston, Natasha ^a   Montgomery, William ^b   Christova, Laura ^c   Fitzgerald, Paul ^a  

^a Alfred Hospital ^*  (Australia)

^b ELI LILLY AUSTRALIA PTY LTD   (Australia)

^c M TAG   (Australia)

Author keywords

Antipsychotic agents; Health care costs; Outcomes research; Psychosocial aspects; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUSTRALIA; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DISABILITY; DISEASE SEVERITY; EMPLOYMENT STATUS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MONOTHERAPY; POSITIVE AND NEGATIVE SYNDROME SCALE; PROGNOSIS; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL INTERACTION;

ADULT; ANTIPSYCHOTIC AGENTS; AUSTRALIA; COHORT STUDIES; COMMUNITY MENTAL HEALTH SERVICES; EFFICIENCY, ORGANIZATIONAL; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HEALTH STATUS; HUMANS; LONGITUDINAL STUDIES; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PERSONAL SATISFACTION; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 36249011869     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670701689410     Document Type: Article

References (25)

1. Nasrallah, HA, Schwarzkopf, SB, Olson, SC and Coffman, JA. (1990) Gender differences in schizophrenia on MRI brain scans. Schizophr Bull, 16, pp. 205-210.
2. Attkisson, C., Cook, J. and Karno, M. (1992) Clinical services research. Schizophr Bull, 18, pp. 561-626.
3. Lehman, AF. (1996) Evaluating outcomes of treatments for persons with psychotic disorders. J Clin Psychiatry, 57, pp. 61-67.
4. Lehman, AF, Fischer, EP and Postrado, L. (2003) The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): An instrument to assess outcomes of schizophrenia care. Schizophr Bull, 29, pp. 247-256.
5. Fitzgerald, PB, Montgomery, W. and de Castella, AR (2007) Australian Schizophrenia Care and Assessment Programme: Real-world schizophrenia: economics. Aust N Z J Psychiatry, 41, pp. 819-829.
6. Ascher-Svanum, H., Faries, D., Zhu, B., Ernst, F., Swartz, M. and Swanson, J. (2006) Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry, 67, pp. 453-460.
7. Burns, T., Christova, L. and Cooper, S. (2006) Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: A naturalistic cohort study. Acta Psychiatr Scand, 113, pp. 126-134.
8. Kay, SR, Fiszbein, A. and Opler, LA. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 13, pp. 261-276.
9. Montgomery, S. and Asberg, M. (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry, 134, pp. 382-389.
10. First, M. (1996) Effective use of the global assessment of functioning (GAF) scale in a managed care environment, Columbia University, New York
11. Munetz, MR and Benjamin, S. (1988) How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry, 39, pp. 1172-1177.
12. Simpson, G. and Angus, J. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand, pp. 11-19.
13. Heinrichs, DW, Hanlon, TE and Carpenter Jr, WT (1984) The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull, 10, pp. 388-398.
14. Hawthorne, G., Richardson, J. and Osborne, R. (1999) The Assessment of Quality of Life (AQoL) instrument: A psychometric measure of health-related quality of life. Qual Life Res, 8, pp. 209-224.
15. Wertheimer, AI. (1986) The defined daily dose system (DDD) for drug utilization review. Hosp Pharm;: 233-234, 239-241, 21, p. 258.
16. Methodology WCCfDS. ATC/DDD index 2005: About the ATC/DDD system.
17. Fitzgerald, PB, De Castella, AR and Filia, KM (2003) A longitudinal study of patient- and observer-rated quality of life in schizophrenia Psychiatry Res, 119, pp. 55-62.
18. Ciompi, L. (1988) Learning from outcome studies. Toward a comprehensive biological-psychosocial understanding of schizophrenia. Schizophr Res, 1, pp. 373-384.
19. Andrews, G., Sanderson, K., Corry, J., Issakidis, C. and Lapsley, H. (2003) Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry, 183, pp. 427-435.
20. Andrews, G., Issakidis, C., Sanderson, K., Corry, J. and Lapsley, H. (2004) Utilising survey data to inform public policy: Comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry, 184, pp. 526-533.
21. Ragin, AB, Pogue-Geile, M. and Oltmanns, TF. (1989) Poverty of speech in schizophrenia and depression during in-patient and post-hospital periods. Br J Psychiatry, 154, pp. 52-57.
22. Quinlan, DM, Schuldberg, D., Morgenstern, H. and Glazer, W. (1995) Positive and negative symptom course in chronic community-based patients. A two-year prospective study. Br J Psychiatry, 166, pp. 634-641.
23. Yuen, O., Caligiuri, MP, Williams, R. and Dickson, RA. (1996) Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures. Br J Psychiatry, 168, pp. 702-708.
24. Dollfus, S., Petit, M. and Menard, JF. (1993) Relationship between depressive and positive symptoms in schizophrenia. J Affect Disord, 28, pp. 61-69.
25. Chalamat, M., Mihalopoulos, C., Carter, R. and Vos, T. (2005) Assessing cost-effectiveness in mental health: Vocational rehabilitation for schizophrenia and related conditions. Aust N Z J Psychiatry, 39, pp. 693-700.